残留病灶是化疗难治或复发ALL患者异基因移植前的强预后标志
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is one of the curative treatment options for acute lymphoblastic leukaemia (ALL).…
要点
- 骨髓原始细胞≥10%是与预后最显著相关的危险因素。
核心结论
- 骨髓原始细胞是与移植后预后最显著相关的因素,移植前控制原始细胞对改善预后重要。
研究设计与样本
- 多中心回顾性队列研究,纳入663例非CR状态接受allo-HSCT的成人ALL患者。
主要发现
- 多因素分析识别5项预后危险因素:年龄≥50岁、骨髓原始细胞≥10%、体能状态差、HCT合并症指数高、复发疾病状态。
- 骨髓原始细胞是与预后最显著相关的因素。
关键数值与推荐
- 骨髓原始细胞≥10%被列为预后危险因素。
- 年龄≥50岁被列为预后危险因素。
- 预测评分系统基于年龄、骨髓原始细胞、体能状态、HCT合并症指数和疾病状态分层2年OS。
临床怎么用
- 对非CR状态拟行allo-HSCT的成人ALL患者,应关注移植前骨髓原始细胞水平。
- 可参考包含年龄、骨髓原始细胞、体能状态、HCT合并症指数和疾病状态的评分系统进行预后分层。
局限性
- 本研究为回顾性队列研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is one of the curative treatment options for acute lymphoblastic leukaemia (ALL). However, the outcomes in patients transplanted without complete remission (non-CR) have not yet been fully reported, and detailed analyses are required to identify subgroups in which optimal prognosis is expected and to optimize pre-transplant therapeutic strategies. Hence, we performed a multicentred retrospective cohort study including a total of 663 adult ALL patients transplanted at non-CR status; the median bone marrow (BM) blast counts at HSCT was 13·2%, and 203 patients (30·6%) were treated at primary induction failure status. The overall survival (OS) was 31·1% at two years, and the multivariate analyses identified five prognostic risk factors, including older age (≥50 years), increased BM blasts (≥10%), poor performance status, high haematopoietic cell transplantation (HCT)-comorbidity index, and relapsed disease status, among which BM blast was the most significantly related. A predictive scoring system composed of these risk factors clearly stratified OS (15·6-59·5% at two years). In conclusion, this is the first large-scale study to analyze the correlation of patient characteristics with post-transplant prognosis in ALL transplanted at non-CR status. The importance of blast control before HSCT should be focused on for better patient prognosis.
引用
- Nakamura M, Arai Y, Hirabayashi S, et al. Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation. Br J Haematol. 2021. PMID: 34159580. doi:10.1111/bjh.17646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。